What distinguishes survodutide from GLP-1-only agonists in research?

Survodutide engages both the glucagon receptor and the GLP-1 receptor, whereas semaglutide-class compounds act at GLP-1 alone. The added glucagon-receptor axis is why it is used to study energy expenditure and hepatic outcomes in comparison to single-receptor agonists.

Is survodutide an approved drug?

No. Survodutide is an investigational compound in ongoing research and clinical development. We supply it strictly as a laboratory reference peptide with lot-specific analytical documentation; it is not offered for any human or therapeutic use.

Home CatalogSurvodutide

2D Molecular Structure

CID: 171378821
Standard InChIKey: MEDXQFAHWBMVIM-PCLHIQTFSA-N
FDA UNII: 2ALA66NS64
Residue Count: 29 AA
Structural Modifications: Ac4c (1-aminocyclobutane-1-carboxylic acid) at position 2
C-terminal amide (–NH2)
Lys24 side chain amide-linked to the GSGSGG spacer and γGlu-C18 fatty-diacid conjugate
No disulfide

metabolic Research

Survodutide

Also known as: BI 456906, BI-456906

Investigational dual glucagon (GCGR) / GLP-1 receptor agonist peptide, studied as a next-generation incretin-pathway research compound.

CAS Number: 2805997-46-8
Molecular Formula: C192H289N47O61
Molecular Weight: 4232 g/mol
Purity: Batch-specific
Form: Lyophilized powder
Enquiry Sizes: Research vial • Bulk / custom fill (quote required)
Peptide Sequence29 residues: Subunit 1: His-Ac4c-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-Lys-Trp-Leu-Glu-Ser-Ala-NH2; Subunit 2: Gly-Ser-Gly-Ser-Gly-Gly (amide-linked to Lys24 and bearing the γGlu-C18 fatty-diacid conjugate)

Compliance Notice: All products supplied by BioTech Pharma are intended strictly for laboratory research and development use only. They are not intended for human or veterinary use, diagnosis, treatment, or consumption of any kind. By submitting an enquiry, the requester confirms they are a qualified researcher or institution and accepts full responsibility for compliant handling and use.

Configure Your Request

Pack size

Quantity (vials / units)

Lot documentation to request

Batch certificate of analysis (CoA)Full analytical package (HPLC chromatogram + LC-MS data)Lead-time, stock & shipping-condition confirmation

Documentation requests are reviewed against the records available for the applicable lot. Availability, methods, and values must be confirmed for the specific enquiry and are not promised in advance.

Form supplied: Lyophilized powder. Your selections are carried into the quote request automatically.

Request a Quote Wholesale Inquiries

Overview

Survodutide (development code BI 456906) is a synthetic, acylated peptide engineered as a dual agonist of the glucagon receptor (GCGR) and the glucagon-like peptide-1 (GLP-1) receptor. It carries a C18 fatty-acid conjugate that mediates albumin binding, together with sequence modifications that remove a dipeptidyl peptidase-4 cleavage site, features intended to extend its circulating half-life in experimental systems. Its molecular formula (C192H289N47O61) is defined in the PubChem compound record.

As an investigational molecule, survodutide is being characterized in preclinical pharmacology and clinical development for metabolic indications; published preclinical work has described its balanced GCGR/GLP-1 activity relative to single-receptor agonists. Any references to development status describe the research and trial context only and are not claims of established efficacy.

BioTech Pharma supplies survodutide as a lyophilized powder for laboratory research use exclusively. It is not a drug and is not intended for human or veterinary administration. Lot-specific analytical documentation may be available and should be confirmed for the applicable material.

Research Applications

Dual GCGR/GLP-1 receptor agonist pharmacology
Energy-expenditure and hepatic-metabolism models
Comparative incretin-agonist signaling studies
Peptide acylation and albumin-binding chemistry
Obesity- and metabolic-disease model pharmacodynamics

Frequently Asked Questions

Scientific References

Analytical Data

Lot-specific documentation may be available for the applicable material and must be confirmed per enquiry. Where available, it may include:

HPLC purity result
LC-MS identity confirmation
Appearance
Net content

Request the records you need with your quote and we will confirm availability for your batch.

Procurement Details

Availability, lead time, salt / content basis, and cold-chain requirements depend on the specific lot and quantity, so we confirm them per enquiry rather than publishing fixed figures. Request confirmation for your requirements with your quote and our team will respond with details for the applicable batch.

Storage & Handling

Lyophilized: store sealed at −20 °C, protected from light and moisture. Reconstituted solutions should be kept refrigerated (2–8 °C); prepared-solution stability is lot-specific and should be determined empirically. Prepared-solution stability should be confirmed for the applicable material.

Related Compounds

Tirzepatide

Dual GIP/GLP-1 receptor agonist peptide studied in incretin-pathway and metabolic research, supplied as a lyophilized powder.

Retatrutide

Triple agonist of GIP, GLP-1, and glucagon receptors — the leading next-generation compound in multi-receptor metabolic research.

Semaglutide

The reference GLP-1 receptor agonist analog — a cornerstone compound for incretin-pathway and appetite-regulation research.